{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:33:27Z","timestamp":1787729607191,"version":"build-2784847793"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","award":["NRF-2022R1A2C1004822"],"award-info":[{"award-number":["NRF-2022R1A2C1004822"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002531","name":"Kyungpook National University","doi-asserted-by":"publisher","award":["20220085"],"award-info":[{"award-number":["20220085"]}],"id":[{"id":"10.13039\/501100002531","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002531","name":"Kyungpook National University","doi-asserted-by":"publisher","award":["M20221026004"],"award-info":[{"award-number":["M20221026004"]}],"id":[{"id":"10.13039\/501100002531","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ijid.2025.107914","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T11:56:17Z","timestamp":1745582177000},"page":"107914","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Adverse events of tuberculosis preventive therapy among individuals with latent tuberculosis infection: A nationwide cohort study in South Korea"],"prefix":"10.1016","volume":"156","author":[{"given":"Sung-Hee","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaehee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwoo","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3467-7805","authenticated-orcid":false,"given":"Jin-Won","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2025.107914_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.02.004","article-title":"Incidence of tuberculosis disease in individuals diagnosed with tuberculosis infection after screening: a population-based cohort study in South Korea","volume":"141","author":"Lee","year":"2024","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2025.107914_bib0002","series-title":"Latent tuberculosis infection: updated and consolidated guidelines for programmatic management","year":"2018"},{"issue":"2","key":"10.1016\/j.ijid.2025.107914_bib0003","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3904\/kjim.2020.029","article-title":"Latent tuberculosis infection: recent progress and challenges in South Korea","volume":"35","author":"Jeon","year":"2020","journal-title":"Korean J Intern Med"},{"issue":"22","key":"10.1016\/j.ijid.2025.107914_bib0004","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMra1405427","article-title":"Latent mycobacterium tuberculosis infection","volume":"372","author":"Getahun","year":"2015","journal-title":"N Engl J Med"},{"issue":"4 Pt 2","key":"10.1016\/j.ijid.2025.107914_bib0005","first-page":"S221","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ijid.2025.107914_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the treatment of latent Tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.ijid.2025.107914_bib0007","unstructured":"Joint Committee for the Revision of Korean Guidelines for Tuberculosis. Korean guidelines for tuberculosis: korea Centers for Disease Control and Prevention; 2024. Available from: https:\/\/www.ksid.or.kr\/rang_board\/inc\/download.php?nocount=1&code=ncov_guide_do&num=6796."},{"issue":"5","key":"10.1016\/j.ijid.2025.107914_bib0008","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults","volume":"379","author":"Menzies","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2025.107914_bib0009","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.rmed.2019.10.005","article-title":"Adverse event and treatment completion rates of a 12-dose weekly isoniazid and rifapentine course for South Korean healthcare workers","volume":"158","author":"Jo","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.ijid.2025.107914_bib0010","article-title":"Consortium CDCTES. Trends in tuberculosis clinicians' adoption of short-course regimens for latent tuberculosis infection","volume":"33","author":"Feng","year":"2023","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"issue":"9","key":"10.1016\/j.ijid.2025.107914_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222810","article-title":"Evaluation and treatment of latent tuberculosis infection among healthcare workers in Korea: a multicentre cohort analysis","volume":"14","author":"Han","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ijid.2025.107914_bib0012","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(19)30575-4","article-title":"Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials","volume":"20","author":"Campbell","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.ijid.2025.107914_bib0013","doi-asserted-by":"crossref","first-page":"e3545","DOI":"10.1093\/cid\/ciaa1169","article-title":"Safety and efficacy of Rifampin or Isoniazid among people with mycobacterium tuberculosis infection and living with Human immunodeficiency Virus or other health conditions: post hoc analysis of 2 randomized trials","volume":"73","author":"Campbell","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"16","key":"10.1016\/j.ijid.2025.107914_bib0014","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.3346\/jkms.2022.37.e128","article-title":"Analysis of adverse drug reactions to first-line anti-tuberculosis drugs using the Korea adverse event Reporting System","volume":"37","author":"Chung","year":"2022","journal-title":"J Korean Med Sci"},{"issue":"1","key":"10.1016\/j.ijid.2025.107914_bib0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/atm.2018.12.10","article-title":"written on behalf of AMEB-DCTCG. Balance diagnostics after propensity score matching","volume":"7","author":"Zhang","year":"2019","journal-title":"Ann Transl Med"},{"issue":"2","key":"10.1016\/j.ijid.2025.107914_bib0016","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/cid\/ciad246","article-title":"A systematic review and meta-analysis of tuberculous preventative therapy adverse events","volume":"77","author":"Melnychuk","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.ijid.2025.107914_bib0017","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/cid\/ciad245","article-title":"Scale-up of Rifapentine and Isoniazid for tuberculosis prevention among household contacts in 2 urban centers: an effectiveness assessment","volume":"77","author":"Hussain","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.ijid.2025.107914_bib0018","article-title":"Uptake and completion of tuberculosis preventive treatment using 12-dose, weekly isoniazid-rifapentine regimen in Bangladesh: a community-based implementation study","volume":"9","author":"Rahman","year":"2023","journal-title":"Trop Med Infect Dis"},{"issue":"4","key":"10.1016\/j.ijid.2025.107914_bib0019","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3947\/ic.2019.51.4.355","article-title":"Screening and treatment of latent tuberculosis infection among healthcare workers at a referral hospital in Korea","volume":"51","author":"Park","year":"2019","journal-title":"Infect Chemother"},{"issue":"2","key":"10.1016\/j.ijid.2025.107914_bib0020","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4168\/aair.2021.13.2.245","article-title":"Severe cutaneous adverse reactions to anti-tuberculosis drugs in Korean patients","volume":"13","author":"Jin","year":"2021","journal-title":"Allergy Asthma Immunol Res"},{"issue":"19","key":"10.1016\/j.ijid.2025.107914_bib0021","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ijid.2025.107914_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9071477","article-title":"Common and rare hematological manifestations and adverse drug events during treatment of active TB: a State of art","volume":"9","author":"Minardi","year":"2021","journal-title":"Microorganisms"},{"issue":"2","key":"10.1016\/j.ijid.2025.107914_bib0023","first-page":"e7112","article-title":"Isoniazid induced pure red blood cell aplasia","volume":"12","author":"Azhar","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.ijid.2025.107914_bib0024","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1378\/chest.42.2.222","article-title":"Pyridoxine-responsive anemia in a patient receiving isoniazid","volume":"42","author":"Redleaf","year":"1962","journal-title":"Dis Chest"},{"key":"10.1016\/j.ijid.2025.107914_bib0025","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-226134","article-title":"Isoniazid-induced pure red cell aplasia","volume":"2018","author":"Holla","year":"2018","journal-title":"BMJ Case Rep"},{"issue":"16","key":"10.1016\/j.ijid.2025.107914_bib0026","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1001\/jama.1957.02980160012003","article-title":"Isoniazid as a cause of optic neuritis and atrophy","volume":"164","author":"Kass","year":"1957","journal-title":"J Am Med Assoc"},{"issue":"10","key":"10.1016\/j.ijid.2025.107914_bib0027","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1164\/rccm.201909-1874ST","article-title":"Treatment of drug-resistant tuberculosis. An official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"200","author":"Nahid","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.ijid.2025.107914_bib0028","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3109\/0886022X.2013.815567","article-title":"Rifampicin-associated acute renal failure and hemolysis: a rather uncommon but severe complication","volume":"35","author":"Manika","year":"2013","journal-title":"Ren Fail"},{"issue":"9","key":"10.1016\/j.ijid.2025.107914_bib0029","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/archinte.162.9.985","article-title":"Rifampin and rifabutin drug interactions: an update","volume":"162","author":"Finch","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijid.2025.107914_bib0030","series-title":"Management and Service Organisation","year":"2016"},{"issue":"2","key":"10.1016\/j.ijid.2025.107914_bib0031","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1172\/JCI129197","article-title":"Opportunities and challenges in using real-world data for health care","volume":"130","author":"Rudrapatna","year":"2020","journal-title":"J Clin Invest"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225001377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225001377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T07:50:44Z","timestamp":1770709844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971225001377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":31,"alternative-id":["S1201971225001377"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2025.107914","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse events of tuberculosis preventive therapy among individuals with latent tuberculosis infection: A nationwide cohort study in South Korea","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2025.107914","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"107914"}}